p53-pS15 is a major focal point in p53 activation to mediate p53-dependent transcription or growth arrest, Ser 15 phosphorylation triggers a sequence of additional sites phosphorylation in p53 (including Ser9, -20, -46 and Thr18) that contribute further to p53 activation 28
Dec 19 2022;23(24)doi:10.3390/ijms232416187
More serious but less common adverse effects observed in trials or associated with this drug class include: Increased heart rate , a class effect seen with GLP-1 receptor agonists [15] [12] Gallbladder disease , including gallstones (cholelithiasis), which has been associated with rapid weight loss and incretin-based therapies more broadly
Lab teams should save the product listing, COA, label record, lot number, storage information, and any available analytical testing documentation